Article Figures & Data
Figures
- Fig 1.
Prognostic differences in subjects with H3F3A (n = 23) versus HIST1H3B/C (n = 11) tumors. A, Kaplan-Meier curve shows a trend that approaches significance in OS between H3F3A versus HIST1H3B/C tumors. B, Kaplan-Meier curve shows no significant difference in PFS between H3F3A versus HIST1H3B/C tumors.
- Fig 2.
Differences in tumor volume enhancing and ADC histogram parameters between histone mutations. A, H3F3A-mutated tumor shows lower tumor volume enhancing (0.08 mL), lower ADC_FLAIR mode (1099 × 10−6 mm2/s), higher ADC_FLAIR skewness (1.41), and higher ADC_FLAIR kurtosis (4.39), relative to (B) a HIST1H3B-mutated tumor (tumor volume enhancing: 3.61 mL; FLAIR_ADC mode: 1558 × 10−6 mm2/s; FLAIR_ADC skewness: −0.039; and FLAIR_ADC kurtosis: 0.33).
- Fig 3.
Prognostic differences in subjects with any histone mutation (n = 34) versus wild-type (n = 15) tumors. A, Kaplan-Meier curve shows no significant difference in OS between mutant versus wild-type tumors. B, Kaplan-Meier curve shows no significant difference in PFS between mutant versus wild-type tumors.
Tables
Patient Characteristic No. (%) or Median (Range) No. of MR imaging studies 50 (100) Sex Male 24 (48) Female 26 (52) Median age at registration (range) (yr) 6 (3.3–17.5) Molecular subgroups MGMT–/EGFR– 28/48 (58) MGMT–/EGFR+ 14/48 (29) MGMT +/EGFR– 3/48 (6) MGMT +/EGFR+ 3/48 (6) Unassigned 2 Mutational statusa Any histone mutation 34/49 (69) Wild-type 15/49 (31) Histone mutation (among patients with any histone mutations)a H3F3A 23/34 (68) HIST1H3B 8/34 (24) HIST1H3C 3/34 (9) Median follow-up time (range) (mo) 10.9 (0.4–33.4) ↵a One patient with both H3F3A and HIST1H3B histone mutations was excluded.
- Table 2:
Association of imaging predictors and variant histone mutation (H3F3A versus HIST1H3B/C) (n = 34)
Imaging Parameters (Median) (Range) No. Variant Histone Mutation Wilcoxon P H3F3A (n = 23) HIST1H3B and HIST1H3C (n = 11) FLAIR/T2 tumor volume 33 35.1 (10.7–70.9) 40.3 (11.6–63) .4 Tumor volume cyst/necrosis (mL) in patients with cyst/necrosis 16 0.8 (0.07–8.1) 2.1 (0.09–4.1) .8 Presence of necrosis (yes vs no) in patients with enhancing tumor volume >0 22 11/16 (69%) 5/6 (83%) .6a Tumor volume enhancing (mL) in patients with enhancing tumor volume >0 22 2.5 (0.08–12.4) 6.3 (3.6–15.2) .04b Presence of enhancement (yes vs no) 31 16/21 (76%) 6/10 (60%) .4a Mean ADC_FLAIR × 10−6 mm2/s 31 1306 (893.9–1915.2) 1411 (1168.8–2098.3) .06 Median ADC_FLAIR × 10−6 mm2/s 31 1260 (906.7–1913) 1370 (1189.4–2146.0) .03b Mode ADC_FLAIR × 10−6 mm2/s 31 1257 (895.5–1886.4) 1396 (1150.8–2214.4) .02b Skewness ADC_FLAIR 29 1 (−0.6–2.0) 0.03 (−1.3–0.9) .009b Kurtosis ADC_FLAIR 29 1.8 (−0.3–8.2) 0.3 (−1.1–2.4) .03a - Table 3:
Association of imaging predictors with mutational status (any histone mutation versus wild-type) (n = 49)
Imaging Parameters (Median) (Range) No. Any Histone Mutation (n = 34) Wild-Type (n = 15) Wilcoxon P Mean ADC_T2-FLAIR/T2 × 10−6 mm2/s 45 1360 (893.9–2098.3) 1327 (1040.4–1838.5) .9 Median ADC_T2-FLAIR/T2 × 10−6 mm2/s 45 1309 (906.7–2146.0) 1316 (952.0–1925.7) .9 Mode ADC_T2-FLAIR/T2 × 10−6 mm2/s 45 1311 (895.5–2214.4) 1342 (893.8–1965.4) .99 Skewness ADC_T2-FLAIR/T2 42 0.5 (−1.3–2.0) 0.8 (−0.9–2.8) .4 Kurtosis ADC_T2-FLAIR/T2 42 1.1 (−1.1–8.2) 2.0 (−0.1–9.0) .1
